Answers are grounded in this paper and cite their sources.
Human pegivirus 1 (HPgV-1) is a widespread RNA virus detected in lymphoid and other hematopoietic cells, although its principal cellular reservoir in vivo remains uncertain. In people living with HIV-1 (PLWH), persistent HPgV-1 viremia has been associated with higher CD4+ T-cell counts, lower HIV-1 viral loads, and improved clinical outcomes, although these associations are inconsistent across studies. This review summarizes epidemiological, clinical, and experimental data on the biology of HPgV-1 and HPgV-2, their interactions with HIV-1, HCV, and the host immune system, as well as the influence of antiretroviral therapy and viral genetic variability. The strongest mechanistic evidence concerns HPgV-1 and includes experimental inhibition of HIV-1 entry or replication by the E2, NS3, and NS5A proteins; modulation of chemokines and CCR5/CXCR4 coreceptors, TCR/IL-2/STAT5 signaling, and NK-cell functions; and associations with Fas/CD95 expression and interferon-dependent responses. Clinical associations may vary according to HPgV viremia status, anti-E2 seropositivity, ART exposure, and cohort characteristics, while data on HPgV-2 remain limited. The potential impact of HPgV on HIV persistence and proviral reservoirs is of particular interest, but direct evidence of changes in reservoir size or composition is lacking. HPgV should therefore be considered a model of natural virus-induced immunomodulation and a potential source of therapeutic molecules, although their clinical efficacy and long-term safety remain to be established.
No takes yet. Share an insight, caveat, or question.
Kiryakina et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: